Cleveland Clinic to test new drug for early detection of multiple sclerosis

Written by Alan Condon | January 29, 2020 | Print  |

Myeliviz, a new drug to help diagnose multiple sclerosis in its earlier stages was recently approved by the FDA for human clinical trials.

The drug aims to provide new evidence to help diagnose MS and evaluate the scope of damage inflicted on the central nervous system.

Researchers from Cleveland-based Case Western Reserve University developed the drug, which will be tested in healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.

Administered through an IV before a PET scan, Myeliviz targets and binds to myelin, the casing surrounding nerves affected by MS.

The National Institutes of Health provided a $1.7 million grant to make the trial possible.

More articles on biologics:
Dr. Fred Naraghi: Cervical disc replacement, spinal fusion will continue to be dominant procedures
$186M in Q4 sales delivered by Novartis gene therapy for spinal muscular atrophy
HSS opens 1st Florida hospital, 2nd new facility in 1 week

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months